Infection: Nutritional Interactions by Ghattas, H
Cox, SE; Doherty, C; Atkinson, SH; Nweneka, CV; Fulford, AJ;
Ghattas, H; Rockett, KA; Kwiatkowski, DP; Prentice, AM (2007)
Haplotype Association between Haptoglobin (Hp2) and Hp Promoter
SNP (A-61C) May Explain Previous Controversy of Haptoglobin and
Malaria Protection. PLoS One, 2 (4). e362. ISSN 1932-6203
Downloaded from: http://researchonline.lshtm.ac.uk/10175/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution http://creativecommons.org/licenses/by/2.5/Haplotype Association between Haptoglobin (Hp2) and
Hp Promoter SNP (A-61C) May Explain Previous
Controversy of Haptoglobin and Malaria Protection
Sharon E. Cox
1*, Conor Doherty
2, Sarah H. Atkinson
1,2, Chidi V. Nweneka
2, Anthony J. C. Fulford
1, Hala Ghattas
1, Kirk A. Rockett
3, Dominic P.
Kwiatkowski
3, Andrew M. Prentice
1
1Medical Research Council (MRC) International Nutrition Group, London School of Hygiene and Tropical Medicine (LSHTM), London, United Kindgom,
2Medical Research Council (MRC) Keneba, MRC Laboratories, The Gambia, 3Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom
Background. Malaria is one of the strongest recent selective pressures on the human genome, as evidenced by the high levels
of varying haemoglobinopathies in human populations–despite the increased risk of mortality in the homozygous states.
Previously, functional polymorphisms of Hp, coded by the co-dominant alleles Hp1 and Hp2, have been variously associated
with several infectious diseases, including malaria susceptibility. Methodology/Principal Findings. Risk of a clinical malarial
episode over the course of a malarial transmission season was assessed using active surveillance in a cohort of Gambian
children aged 10–72 months. We report for the first time that the major haplotype for the A-61C mutant allele in the promoter
of haptoglobin (Hp)–an acute phase protein that clears haemoglobin released from haemolysis of red cells–is associated with
protection from malarial infection in older children, (children aged $36 months, .500 parasites/ul and temperature .37.5uC;
OR=0.42; [95% CI 0.24–0.73] p=0.002) (lr test for interaction, ,36 vs $36 months, p=0.014). Protection was also observed
using two other definitions, including temperature .37.5uC, dipstick positive, plus clinical judgement of malaria blinded to
dipstick result (all ages, OR=0.48, [95% CI 0.30–0.78] p=0.003; $36 months, OR=0.31, [95% CI 0.15–0.62] p=0.001). A similar
level of protection was observed for the known protective genetic variant, sickle cell trait (HbAS). Conclusions/Significance.
We propose that previous conflicting results between Hp phenotypes/genotypes and malaria susceptibility may be explained
by differing prevalence of the A-61C SNP in the populations studied, which we found to be highly associated with the Hp2
allele. We report the -61C allele to be associated with decreased Hp protein levels (independent of Hp phenotype), confirming
in vitro studies. Decreased Hp expression may lead to increased oxidant stress and increased red cell turnover, and facilitate
the development of acquired immunity, similar to a mechanism suggested for sickle cell trait.
Citation: Cox SE, Doherty C, Atkinson SH, Nweneka CV, Fulford AJC, et al (2007) Haplotype Association between Haptoglobin (Hp2) and Hp Promoter
SNP (A-61C) May Explain Previous Controversy of Haptoglobin and Malaria Protection. PLoS ONE 2(4): e362. doi:10.1371/journal.pone.0000362
INTRODUCTION
Haptoglobin (Hp) is an acute phase protein that binds haemoglo-
bin released during the intravascular lysis of erythrocytes. Cell-free
plasma haemoglobin is a potent pro-oxidant and haptoglobin is
thought to be important in removing it from circulation and
recycling the iron component for erythropoeisis via the reticulo-
endothelial system and binding of CD163 on circulating mono-
cytes and macrophages [1].
Haptoglobin phenotypes and genotypes have been variously
reported to be associated with a range of disease conditions,
reviewed by McDermid et al [2], including viral load and mortality
in HIV [3,4,5], Chaga’s disease [6] diabetes-associated cardiovas-
cular disease [7,8], diabetes [9], gestational diabetes [10] and in
some studies, susceptibility to malaria [4,11,12,13], although other
studies have not reported such an association [14,15].
In humans, Hp is polymorphic with two co-dominant alleles,
Hp1 and Hp2 encoded by a single gene on chromosome 16, result-
ing in three phenotypes Hp11, Hp12 and Hp22. Unlike Hp11 and
Hp12, Hp22 exists as large circular polymers, whilst Hp12 pheno-
types form a variety of polymer formations. Hp22 is reported to
have decreased binding affinity for free haemoglobin [16,17] and
has been associated with markers of oxidant stress [7,18,19] and
iron delocalisation [20]. Several studies have demonstrated plasma
Hp concentrations to be affected by Hp phenotype/genotype
[18,21,22], with circulating concentrations observed in the order
of Hp11.Hp12.Hp22. Hp is also thought to affect immune
regulation. The different phenotypes have been associated with the
Th1/Th2 balance of cytokine response [23,24], possibly through
cross-linking of CD163 on monocytes and macrophages [1,24,25]
and with lymphocyte subset and levels of CD22 expression [26].
Additionally, Hp is reported to bind to the integrin receptor
CD11b/CD18, primarily expressed on monocytes and involved in
inflammation, phagocytosis and cytoadherence [27]. In relation to
malaria, Hp has been demonstrated to have direct toxic effects on
malarial parasites in vitro [28] and Hp knockout mice have been
reported to have higher parasite densities than wild type mice [29].
A fourth phenotype, Hp0 (i.e. no detectable circulating hapto-
globin) has been reported in various African populations. In cross-
sectional studies, the occurrence of ahaptoglobinaemia has been
associated with malaria endemicity [30,31,32] and in some studies
with parasite density [22]. Furthermore, haptoglobin concentra-
tions have been shown to increase after malaria treatment [33]. It
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lead to depletion of circulating Hp as it is saturated and taken up
by monocytes and macrophages–via CD163. Hence the main
cause of apparent ahaptoglobinaemia may be environmental.
However, additional factors appear to act to determine Hp levels
as the prevalence of ahaptoglobinaemia was not increased in
children under 5 yrs of age with higher parasite densities com-
pared to adults with low parasite densities [32,33]. More recently,
haptoglobin concentrations have been associated with parasite
density, interacting with age, plus haptoglobin genotype in
Gabonese children [22] and alpha thalassaemia genotype in
Papua New Guinean children [21].
In the Japanese a genetic basis of ahaptoglobinaemia has been
identified as the homozygous inheritance of a deletion spanning
the entire Hp gene (Hp-del) [34]. So far this allele has not been
detected in African populations [35]. However, two single
nucleotide polymorphisms (SNPs) in the promoter region of the
Hp gene, A-61C (rs5471) and C-101G (rs5470) have been
associated with ahaptoglobinaemia and hypohaptoglobinaemia,
respectively in Ghanaian samples, free from malarial parasitaemia
[35]. We have investigated the prevalence of these SNPs and of
Hp-del in a population of Gambian children, and their association
with Hp genotype, Hp concentration and risk of malaria.
METHODS
Patients and methods
Ethical permission for the study was granted by the Gambian
Government and Medical Research Council Ethics Committee,
and Gambian National DNA Collection Guidelines were followed
regarding the handling of genetic material and information.
Parental written informed consent was obtained for all study
participants.
The main study described consists of a longitudinal study with
active surveillance for malaria and febrile episodes across the
malaria transmission season in 2003, in children aged 10–
72 months. This was conducted in eight rural villages in the West
Kiang District of The Gambia, including the village of Keneba in
which the Medical Research Council (MRC) clinic and labora-
tories are situated. Additionally two cross-sectional surveys of
malarial parasitaemia prevalence were conducted, before
(N=873) and after (N=801) the malaria transmission season in
July and December 2003.
At the cross-sectional surveys, children found to have anaemia
(Hb,80 g/l) were treated with iron sulphate supplements (30 mg/
day for 30 days), whilst children found to have malaria parasites of
any density were treated with chloroquine and suphadoxine-
pyrimethamine as per Gambian government treatment guidelines.
The definition of malaria used for the cross-sectional survey was
slide-confirmed parasitaemia of any density.
The longitudinal surveillance study enrolled 889 children.
Children were not eligible if they were known to have sickle cell
disease or were found to have protein-energy malnutrition as
determined by weight-for-height z-score of less than minus three
(such children were referred to the Keneba supplement centre for
treatment). DNA samples were available from 735 of the enrolled
children. One child later found to be homozygous for HbS was
excluded from the final analysis. Complete genetic and clinical
follow up data were available for 599 children, whilst 1 further
child was excluded from the final analysis as lost to follow up after
only 1 week. Village assistants measured children’s temperatures
twice weekly and children with recorded temperature (.37.5uC)
were seen by the study clinician at a twice weekly mobile clinic in
each village. In addition, mothers were encouraged to bring their
children to the mobile clinic if they felt their children had fever or
was unwell. Those children with an increased temperature
(.37.5uC axilla) or whose mothers reported a history of fever in
the previous 48 hours were tested for malaria infection using
a dipstick (ICT malaria Pf/Pv, AMRAD-ICT, Brookvale, Austra-
lia). Children with positive dipstick results had a 4 ml blood
sample collected and parasitaemia confirmed by microscopy (12
out of the 271 positive dipstick tests were negative by slide result).
Three different definitions were used to define malarial episodes: –
(i) recorded temperature .37.5uC within the previous 3 days, plus
a positive malarial dipstick, confirmed by microscopy to have
asexual stage parasites .500/ul of blood (N=255); (ii) as for (i) but
including all those that were dipstick positive (N=271) (iii) dipstick
positive with a recorded temperature .37.5uC within the previous
3 days, plus clinical judgement of malaria by the study clinician,
initially blinded to the dipstick result (N=167). Malaria as a cause
of subsequent febrile episodes was determined based on clinical
judgement and few were confirmed by dipstick or microscopy. All
children seen by the study clinician at these clinics received treat-
ment as appropriate, either in the field or at MRC Keneba clinic
and free of charge. Thus all first malaria episodes were detected
and confirmed by microscopy.
Laboratory procedures and statistical analysis
Blood films were stained with Field’s and Giemsa, and examined
for malaria parasites according to standard methods. Frozen
plasma samples were analysed at the MRC Human Nutrition
Research Laboratories Cambridge, UK. Plasma haptoglobin and
CRP concentrations were measured by immunoturbidimetry,
Tina-quant on a Hitachi 912 Bioanalyser (Roche Systems, Basel,
Switzerland). DNA was extracted from peripheral blood leuko-
cytes using standard methods [36] and quantified using the
PicoGreen assay with measurement of flouresence by the TECAN
SPECTRAfluor Plus fluorimeter. Frozen aliquots of DNA were
shipped to The Wellcome Centre for Human Genetics, Oxford,
UK, where all genotyping was conducted using genomic DNA.
Haptoglobin was genotyped by allele-specific PCR adapted from
a method published by Koch et al. [37]. This method determines
the Hp1 and Hp2 alleles but does not distinguish between the ‘‘F’’
and ‘‘S’’ subtypes of the Hp1 and Hp2 alleles and therefore avoids
potential misclassification based on the presence of different com-
binations of these sub-types [38]. The presence of the previously
reported haptoglobin deletion was assessed using the method of
Koda et al. [39] who kindly provided control DNA samples known
to be heterozygous and homozygous for this deletion. PCR pro-
ducts were resolved in 1% agarose gels, stained with ethidium
bromide and visualised under UV light. Details are provided in the
supplementary material, Tables S1 and S2.
Sequenom
H MassARRAY
H (Sequenom
H, Hamburg Germany)
was used to genotype the following SNPs according to manu-
facturer’s instructions: Haptoglobin promoter SNP’s A-61C
(rs5471) and C-101G (rs5470), HbS (rs334: haemoglobin–sickle),
plus the A-376G (rs1050829) SNP in G6PD (glucose-6-phosphate
dehydrogenase) resulting in mild enzyme deficiency, type A
phenotype [40]. We did not type the G-202A SNP, which when
inherited with -376G allele results in a more severe phenotype, A-
[40] as we have previously found the prevalence to be very low in
this population (Atkinson-SH, unpublished data). Primer details
are given in the supplementary material, Table S3.
Due to the unexpected lack of homozygotes for the -61C allele
of the Hp promoter SNP (see results section below), we generated
two control plasmids for the A-61C SNP, one containing the A
allele and the other the C allele. Briefly, gDNA was PCR amplified
using the first-round primers in Table S3 as per the Sequenom
Haptoglobin and Malaria
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heterozygote during genotyping. The PCR product obtained was
cloned into the pGEM-T vector (Promega, Southampton, UK)
according to the manufacturer’s protocol. Colonies were screened
by PCR plus restriction enzyme digestion with BpmI (NEB,
Hitchin, UK) (Figure S1). Positive colonies for each allele were
grown and plasmid DNA prepared. The plasmids were then
genotyped individually or as a mixture using the Sequenom
H
MassARRAY
H. This confirmed that the assay was able to correctly
identify the AA, AC and CC genotypes (data not shown).
Haplotypes for the two Hp promoter SNPs and the haptoglobin
gene alleles–Hp1&Hp2–were constructed using SNPHAP 1.1 [41].
Analyses were conducted using STATA version 9 (Stata,
StataCorp LP, Texas, USA). Associations between genotypes
were tested using Pearson’s Chi-square test and binomial
regression, which was also used to determine whether alleles were
geographically clustered.
Analysis of associations between Hp haplotypes, HbS and G6PD
genotypes and the prevalence of malarial parasitaemia (any density)
at the cross sectional surveys, was performed using logistic
regression controlling for age, sex and village. Analysis of
associations between Hp haplotypes, HbS and G6PD genotypes
and risk of at least one malarial episode, assessed in the longitudinal
cohort,was performed byboth Cox-regression–timeto firstmalarial
event, and logistic regression, whereby children were classified as
having had one or more malarial episodes or none. Children who
did not have data for all of the genes tested were not included in this
analysis. The mean follow up time of the 598 children included in
the analysis was 99 days (SD 9.6) whilst the minimum and
maximum follow up times were 21 and 102 days. No material
differences were observed between models using Cox-regression
time to first event or logistic regression. Hence, here we report
results of the logistic regression models. Age, sex and village were
included in all models a-priori. Hp haplotypes were fitted as a dose
effect, coded by the number of copies (0, 1 or 2). Thereafter if
a haplotype was found to be associated, we attempted to test for
a dominance effect (i.e. to test if the effect per copy was linear or
differed in the heterozygote or homozygote condition). However,
the small numbers of individuals with more than 1 copy of the
relevant haplotype resulted in break-down of the assumptions of the
model and the results were uninterpretable. Children who were
found to be HbSS were excluded from analyses and therefore sickle
genotype was fitted as a simple binary variable, whilst G6PD A376-
G wasfittedtakingintoaccountthephenotypicaffectsofsex-linkage
by coding males with one copy of the mutant 376-G allele (G6PD
AZ) and females with two copies of the 376G allele (G6PD AA),
similarly.
Malarial parasitaemia at the pre-season cross-sectional survey
was assessed but not found to be associated with risk of subsequent
malaria during surveillance.
Comparison of concentrations of plasma haptoglobin (log-
transformed) measured at malaria episodes and at convalescence
was assessed using a paired student’s t-test with levels less than the
minimum detectable level (MDL, 20 ng/dl) assigned a value of
10 ng/dl. However, a considerable proportion of samples, espe-
cially at convalescence were below the MDL. Therefore further
analyses were conducted of the proportions of samples above and
below the MDL–at malaria and convalescence–and associations
withHphaplotypes andgenotypes usingmultiple logisticregression.
RESULTS
Genotypes were available for between 665 (haptoglobin) and 755
(G6PD–G376-A) children for each of the six genes tested. The
overall prevalence of the genotypes for each gene did not vary
between the total number and the 598 children included in the
final analysis of the longitudinal study.
The prevalence of the different genotypes for the 598 children
included in the final analysis of the longitudinal study is presented
in Table 1. Similar to that previously reported in a smaller
populations of Ghanaians [35,42] we did not detect the presence
of the Hp-del allele, of which the homozygous inheritance has
been proven to be the major cause of ahaptoglobinaemia in Asian
populations [34,39]. Additionally, we did not detect the presence
of any homozygotes for the haptoglobin promoter A-61C allele.
The distribution of genotypes for this promoter SNP and also,
haptoglobin itself, were not in Hardy Weinberg equilibrium.
Haplotypes were constructed for the haptoglobin gene and the
two haptoglobin promoter SNPs. Four common and two un-
common haplotypes were detected (Table 2). These indicated
that, as previously reported [35] the -61C allele was highly
associated with the Hp2 allele (haplotype D: 101C, -61C, Hp2–
13%), whilst the -101G allele was associated with the Hp1 allele
(haplotype E: -101G, 61A, Hp1–13%) (Table 2). No haplotypes
containing the mutant alleles for both of the promoter SNPs were
detected. However, there were a small number of combined
heterozygotes for the promoter SNPs 4% (24/598) with co-
inheritance of the two common mutant haplotypes–D&E. The
association between the -61C allele and the Hp2 allele, combined
with the observed lack of homozygotes for -61C likely explains why
these genes were not observed in Hardy Weinberg equilibrium.
Multiple binomial regression analysis of the Hp 2 allele revealed
geographic clustering in some villages (2/9) plus independent
associations with the number of -61C and -101G alleles (coefficient
2.65, OR=14.2 [95% CI 5.1–39.4], p,0.001&21.32, OR=0.27
[95% CI 0.2–0.4], p,0.001, respectively) and also G6PD
deficiency, whereby male hemizygotes (AZ) and female homo-
zygotes (AA) were less likely to have the Hp2 allele (coefficient -
0.83, OR=0.44 [95% CI 0.3–0.7], p=0.002). No associations
between the haptoglobin promoter SNPs and HbS and G6PD
deficiency alleles were detected.
The A-61C SNP is associated with protection from
malaria
Cross-sectional surveys of malarial parasitaemia The
prevalence of malarial parasitaemia was 8.6% at both the pre-
season (50/585) and post-season surveys (49/568), limited to those
with Hp haplotype data available. There were no differences in the
prevalence of malaria between individuals with and without
complete genotype data available (data not shown). At the pre-
season cross-sectional survey, in multiple logistic regression,
Table 1. Prevalence of tested genotypes in individuals
included in malarial surveillance analysis (N=598)
......................................................................
Gene genotypes
Hp Hp11 21.1% Hp12 57.0% Hp22 21.9%
A-61RC AA 73.4% AC 26.6% CC 0%
C-101RG CC 74.4% CG 24.1% GG 1.5%
HbS HbAA 83.4% HbAS 16.6% HbSS 0%
G6PD
376 BB 56.9% BA 22.9% AA or AZ 20.2%
Hp
del* Hp
WT/WT 100% Hp
WT/del 0% Hp
del/del 0%
*Hp del allele tested for in all samples for which we had not been able to
determine a haptoglobin genotype, due to repeated failure of one or both of
the primer reactions and also in all homozygotes.
doi:10.1371/journal.pone.0000362.t001
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prevalence of malarial parasitaemia (any density) was significantly
decreased in individuals with 1 copy of haplotype ‘‘D’’ (-101C,
-61C, Hp2; OR=0.30 [95% CI 0.12–0.80], p=0.014). As no
homozygotes for -61C were detected there were no individuals with
two copies of this haplotype. No other genotype associations were
detected at this time point. At the post-season survey there was no
evidence for an association with malaria for any of the haplotypes
or with HbAS or G6PD genotypes.
Longitudinal study of malaria risk Of children enrolled in
the longitudinal study, 598 children had complete genotype data,
of which 255 were detected as having at least one malarial episode
as described previously, with a parasite density greater than 500
asexual parasites/ul. Of these children, only three were recorded
as having a subsequent malarial episode–as determined by clinical
judgement by the study clinician. Sex and age groups were evenly
distributed amongst the 598 children included in the final analysis.
Children with one copy of Hp haplotype ‘‘D’’ (-101C, -61C, Hp2)
had a significantly decreased risk of having a malarial episode
(definition (i) .500 parasites/ul and history of or current temp
.37.5uC) (OR=0.66, p=0.043, Table 3), controlling for age
(groupedinyears),sex,villageandHbAS,thelatterofwhichwasalso
protective (Table 3). The protective effect of the ‘‘D’’ Hp haplotype
appeared tobe limited toolderchildren(Figure1) with no apparent
effect in children aged less than three years but a significant effect in
children aged 3 or more years (OR=0.42 [95% CI 0.24–0.73],
p=0.002). Additionally, the interaction between the presence/
absenceofthe‘‘D’’haplotypeand age,treated asabinaryvariableas
more or less than 3 years, was statistically significant (lr test,
p=0.014). There was no difference in the prevalence of the ‘‘D’’ Hp
haplotype between the different age groups (26% vs 25%).
If the definition of a malarial episode was relaxed to include all
those that were dipstick positive (N=271/598), results from the
multivariate analysis were similar for haplotype ‘‘D’’ (OR=0.61,
p=0.012, for all ages. Table 3), with the addition that haplotype
‘‘E’’ (-101G, 61A, Hp1) was found to be significantly associated with
an increased risk of malarial infection (OR=1.50, p=0.031, for all
ages) (Table 3). Both of these effects were limited to children aged
3 years or more (‘‘D’’: OR=0.42, [95% CI 0.24–0.74] p=0.002;
no of copies of ‘‘E’’: OR=1.94 [95% CI 1.15–3.27] p=0.013),
(Figure 2). Finally, a further definition of malaria was tested,
blinded clinical diagnosis of malaria, based on the study clinician’s
Table 2. Prevalence of haplotypes constructed from haptoglobin alleles and haptoglobin promoter SNPs.
..................................................................................................................................................
Distribution of haplotype dose (N=598)
Haplotype C-101G A-61C Hp Haplotype frequency (n=2*598) 0 1 2
A C A 1 36% 226 (38) 313(52) 59 (10)
B C A 2 37% 232 (39) 289 (48) 77 (13)
C C C 1 0.5% 594 (99) 4 (1) 0 (0)
D C C 2 13% 442 (74) 156 (26) 0 (0)
E G A 1 13% 447 (75) 144 (24) 7 (1)
F G A 2 0.5% 594 (99) 4 (1) 0 (0)
*Shaded blocks indicate possession of the mutant allele for the gene indicated.
doi:10.1371/journal.pone.0000362.t002
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Table 3. Genotypes and risk of one or more malarial episodes over the malarial transmission season 2003–children aged 10–
72 months.
..................................................................................................................................................
Risk of malarial episode (.500 parasites/ul)(N=255/598)* OR 95% CI P value
Variable
1 vs zero copies of Haplotype ‘‘D’’ (-101C, -61C, Hp2) 0.66 0.439 0.986 0.043
Per copy of Hp haplotype ‘‘E’’ vs zero copies (-101G, 61A, Hp1) 1.23 0.853 1.781 0.26
HbAS vs HbAA 0.62 0.381 1.008 0.054
Risk of MALARIAL EPISODE (any parasites) N=271/598)**
1 vs zero copies of Haplotype ‘‘D’’ (-101C, -61C, Hp2) 0.60 0.397 0.893 0.012
Per copy of Hp haplotype ‘‘E’’ vs zero copies (-101G, 61A, Hp1) 1.50 1.030 2.167 0.031
HbAS vs HbAA 0.63 0.382 1.003 0.059
Risk of CLINICAL DIAGNOSIS (N=167/598)***
1 vs zero copies of Haplotype ‘‘D’’ (-101C, -61C, Hp2) 0.48 0.296 0.777 0.003
Per copy of Hp haplotype ‘‘E’’ vs zero copies (-101G, 61A, Hp1) 1.22 0.809 1.790 0.32
HbAS vs HbAA 0.51 0.281 0.906 0.019
*Model LR chi2(15)=54.68, Prob .chi2=,0.0001, Pseudo R2=0.0671.
**Model LR chi2(15)=66.71, Prob .chi2,0.0001, Pseudo R2=0.0811.
***Model LR chi2(15)=60.81, Prob .chi2,0.0001, Pseudo R2=0.0859.
Other variables included in all models included age (ordered categorical grouped in years, ,2 as reference group then ,3, ,4, ,5&,6); sex (M vs F) village of residence
(8 villages as an ordered categorical variable).
Clinical diagnosis was based on clinical judgement at presentation by study clinician blinded to positive malarial dipstick and blood film results.
doi:10.1371/journal.pone.0000362.t003
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PLoS ONE | www.plosone.org 4 April 2007 | Issue 4 | e362judgement on examination, plus a positive dipstick result (N=167/
598). Using this definition there was no apparent effect of the ‘‘E’’
haplotype,eitherwhenallagegroupswereincludedorwhenlimited
toolderchildren.Thereremained the protectiveeffectsofhaplotype
‘‘D’’ (OR=0.48, p=0.003, all age groups) (Table 3), whilst the
effects of ‘‘D’’ and also of HbAS were both limited to the older
children (‘‘D’’: OR=0.3 [95% CI 0.15–0.60], p=0.001; HbAS:
OR=0.30[95% CI 0.8–2.4], p=0.008) (Figure 1&2).
Figure 1. Likelihood of one or more malarial episodes associated with presence vs absence of haplotype D (-101C, -61C, Hp2) in all ages combined
and,and .3 years of age (controlling for number of copies of haplotype E, sex, village and HbAS).
doi:10.1371/journal.pone.0000362.g001
Figure 2. Likelihood of one or more malarial episodes per copy of haplotype E (-101G, -61A, Hp1) in all ages combined and,and .3 years of age
(controlling for presence/absence of haplotype D, sex, village and HbAS).
doi:10.1371/journal.pone.0000362.g002
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associated with plasma haptoglobin concentrations
Haptoglobin concentrations were analysed at malaria (n=257, first
detection of a confirmed malarial episode, parasite density .500/ul
plus temperature .37.5uC) and convalescence (n=235, 14 days
later&no detectable parasites) in individuals with Hp haplotype data
available. Alternatively, samples with concentrations less than this
detection limit were coded as being ‘‘hypo-haptoglobinaemic’’.
Contrary to previous reports, the geometric mean concentration of
haptoglobin was increased at malaria compared to convalescence
(56.13 mg/dl vs 27.50 mg/dl, paired t-test, p,0.0001, n=231).
Additionally, the prevalence of hypo-haptoglobinaemia (defined as
values below the assay sensitivity) was significantly increased at
convalescence compared to malarial episodes 54.9% vs 30.0%,
(two-sample test of proportions, p,0.001). As expected, the
frequencies of haplotypes D and E differed between the group
who had a malarial episode and were thus included in analyses of
Hp concentrations and the group in analysis of malarial risk.
Haplotype prevalence was 10.3% and 14.2% for D and E
haplotypes in analyses of haptoglobin concentration compared to
13% for both haplotypes in analysis of malaria susceptibility.
Interestingly, different haplotypes were associated with the risk
of hypo-haptoglobinaemia at malaria and at convalescence.
During malaria, the only haplotype to be associated was haplotype
‘‘A’’ (-101C, -61A, Hp1), associated with a decreased risk (OR=
0.73, p=0.002) (Table 4). Other factors independently associated
with individuals being ‘‘hypo-haptoglobinaemic’’ included age,
CRP concentration and haemoglobin concentrations. At conva-
lescence the possession of the D and E haplotypes with the mutant
alleles of the A-61C and C-101G promoter SNP’s were associated
with an increased (OR=2.3, p=0.023) and decreased risk
(OR=0.41, p=0.002) of hypohaptoglobinaemia (Table 4), whilst
age and haemoglobin concentration were no longer associated.
There was no evidence of an association of HbAS or with G6PD
deficiency with hypo-haptoglobinaemia at either time point.
DISCUSSION
Haptoglobin and malaria association studies
We report for the first time, that the A-61C Hp promoter SNP is
associated with protection from clinical malaria and that this effect
is limited to older children, in this analysis, children between 36
and 72 months. We also confirm the previous report that this SNP
is highly associated with the Hp2 allele [35]. We postulate that this
association with the Hp2 allele might underlie the previous reports
of increased malarial susceptibility associated with Hp11 pheno-
type [12,13,43]. Interestingly, in two case control studies in Sudan
and Southern Ghana the prevalence of the Hp12 phenotype as
well as Hp22 was also much greater in the controls compared to
the cases [12,43] thereby suggesting protection associated with the
Hp2 allele. Similarly, the prevalence of placental parasitaemia was
also reduced in both Hp12 and Hp22 phenotypes compared to
Hp11 [13]. Moreover, differences in population prevalence of the
A-61C and potentially also, the C-101G SNP could conceivably
explain contradictory results as observed in a Northern Ghanaian
population [15]. The lack of an association in a previous Gambian
case-control study could potentially be due to an underestimate of
the Hp2 allele due to the use of the genotyping method by Yano et
al [44], which misclassifies the Hp2ff and Hp2ss subtypes as Hp1
as the African prevalence of these Hp2 subtypes, compared to
Hp2fs is not currently known. The studies of malarial susceptibility
associated with Hp11, and therefore a protective effect of Hp2,
have been criticised for employing Hp phenotyping, in which it is
not possible to determine the phenotype in those with low levels of
Hp (Hp0), which our results suggests is associated with the Hp22
genotype, especially during malarial infection. However, in one
study, the prevalence of Hp0 was reported not to differ between
cases and controls, although absolute numbers were not reported
[43] and in another, no Hp0 phenotypes were found [13]. Finally,
in support of our finding, a recent analysis of a cohort of Kenyan
children with 558 child years of active surveillance for malarial
incidence, demonstrated a significant protective effect of the Hp22
genotype [45]. Furthermore, the simultaneous detection in our
study of protection in individuals heterozygous for HbS, in-
dependent of an effect of the A-61C base substitution, and of
a similar magnitude, adds weight to this association.
Potential mechanisms for a protective effect of the
A-61C SNP from malaria infection
The A-61C SNP has been demonstrated to cause decreased
promoter activity in human HepG2 cells and decreased re-
sponsiveness to IL-6 [35,46] and has been associated with the Hp0
phenotype in non-malarial Ghanaian samples [35]. In our
population of Gambian children, the association between the -
61C allele and undetectable Hp concentration was only evident at
convalescence and not during malarial episodes, when IL-6 is
Table 4. Multiple binary regression analysis of haplotype effects on risk of undetectable plasma haptoglobin (,20 ng/dl) measured
during a malarial episode (.500 parasites/ul) and 14 days later at convalescence and confirmed parasite clearance.
..................................................................................................................................................
AT MALARIA (N=257)*
Variable Coefficient 95% CI P value
Per copy of Hp haplotype ‘‘A’’ vs zero copies (101C, 61A, Hp1) 20.853 21.399 20.307 0.002
Age grouped in years 0.701 0.423 0.989 ,0.001
Haemoglobin g/l 20.050 20.074 20.026 ,0.001
CRP mg/l (log10) 0.703 0.285 1.121 0.001
AT CONVALESENCE (N=235)**
1 vs 0 copies of Hp haplotype ‘‘D’’ (101C, -61C, Hp2) 0.839 0.118 1.561 0.023
Per copy of Hp haplotype ‘‘E’’ vs zero copies (-101G, 61A, Hp1) 20.899 21.470 20.328 0.002
CRP mg/l (log10) 0.381 0.072 0.690 0.016
*LR chi2 (7)=85.57, p,0.0001, Adj R-squared=0.2622
**LR chi2 (6)=26.22, p=0.0001. Adj R-squared=0.0795
doi:10.1371/journal.pone.0000362.t004
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mechanisms affect Hp concentrations, levels of expression and also
rate of clearance, affected by Hp phenotype, either due to
differences in affinity of Hp to CD163 [1] or rates of receptor
mediated endocytosis [8]. At convalescence, assuming the absence
of malaria-induced haemolysis, only levels of expression affect Hp
concentration. Somewhat surprisingly, Hp concentration during
malarial episodes was not found to be associated with parasite
density. However, assuming such a relationship between parasite
density and haptoglobin production exists, the timing of peak
parasitaemia, haemolysis and acute-phase stimulation of Hp
synthesis (and its subsequent sequestration by macrophages) are
unlikely to precisely coincide, making its detection in naturalistic
studies of malarial episodes difficult to detect. In our study, in cases
of confirmed symptomatic malaria (current or record of
temperature .37.5uC, and parasite density .500/ul) age was
negatively correlated with haptoglobin concentration–perhaps
suggesting a decreased acute phase/inflammatory reaction in
older children. Our observation that the protection afforded by the
-61C allele was limited to older children also suggests that this
effect may be mediated via immune mechanisms. The protective
effect of HbAS has been documented in some populations to
increase with age [47] thus suggesting an immune as well as an
innate component to protection. Data from two other studies have
suggested that this may be associated with an increased rate of
development of immune mechanisms and antibody repertoire
[48,49]. Additionally, protection does not appear to extend to mild
or non-symptomatic malaria [50]. A universal mechanism of
innate protection has been proposed for G6PD deficiency, HbAS
and HbC in which there is an increased rate of phagocytosis of
ring-stage parasitised mutant red cells, similar to the mechanism of
removal of senescent or damaged red cells [51]. The link between
an innate mechanism such as suggested above and immune effects
could be via the maintenance of low-grade, chronic infections in
infancy and thus an increased rate of development of immune
mechanisms and antibody repertoire, resulting in protection from
severe/symptomatic malaria in older children HbAS [47,52].
Therefore a similar mechanism to this could be responsible for the
effect of the -61C allele, whereby decreased Hp concentrations
causes increased oxidant stress, increased levels of senescent/
damaged red cells and therefore increased red cell turnover and
perhaps increased phagocytosis of infected red cells. Alternatively,
or in addition, the reduced synthesis of haptoglobin during
malarial infections could have effects on the inflammatory
response and immune functions via reduced signalling through
CD163, CD22 or MAC1 (CD11b/CD18) receptors [23,24,25]
and modulation of the immune response [18,24].
The -61C allele has been found to be the cause of a ‘‘modified’’
phenotypeofHpasassessed ingelelectrophoresisasHp12MOD[53]
thought to be caused by lower expression of the Hp2 polypeptide
compared to the Hp1 polypeptide and the formation of different
polymeric structures. When tested, our observation did not appear
to be due to this phenotype (data not shown). However both Hp12
and Hp22 phenotypes can form a wide variety of polymer
formations [17,53], possibly dependent on levels of haemolysis
and which may differ in their functional capacities, as documented
for haemoglobin binding capacity, [16,17]. It remains to be seen if
the-61Calleleisassociated withcharacteristicpolymerformationin
the Hp12 and Hp22 phenotypes, perhaps through an association
with particular Hp2 and Hp1 ‘‘f’’ and ‘‘s’’ subtypes.
It is not clear why, if there are significant benefits of the
heterozygous state, we did not observe any homozygotes for the
base substitution. In order to rule out methodological error, we
retested the ability of the Sequenom method to detect the -61CC
genotype using cloned -61C or -61A DNA. In all of the samples
tested, the results of the Sequenome method matched those from
restriction digests, suggesting that the lack of detection of -61CC
homozygotes was not due to methodological error (data not
shown). Based on the current results, Hardy Weinberg would
predict 12 individuals homozygote for -61C out of the 750 tested,
suggesting a balanced polymorphism similar to HbS in which the
homozygous inheritance of the -61CC is potentially lethal. In
support of this supposition we have not detected any -61CC
homozygotes in a large cohort of Tanzanian women and in
another cohort of Gambian children (unpublished data). We plan
to test a set of umbilical samples to determine if this genotype can
be detected in a birth cohort. However, one female homozygote
for -61CC out of 17 individuals found to be ahaptoglobinaemic
has been reported from 123 tested [35]. No information on age or
other clinical indices was given, nor were overall genotype
prevelences for this and other SNPs reported, although the allele
frequency of -61C was exactly the same as in our study at 12.6%.
In conclusion, we report an age-dependent protective effect of
the -61C allele-associated Hp haplotype against symptomatic
malaria in Gambian children. We suggest that the mechanism of
protection may be similar to that recently proposed for sickle cell
trait and are currently investigating if this haplotype is associated
with increased oxidant stress, as a critical component of the
proposed mechanism of action.
SUPPORTING INFORMATION
Table S1 Haptoglobin Hp1/Hp2-PCR conditions and primer
sequences-method adapted from Koch et al. 2003
Found at: doi:10.1371/journal.pone.0000362.s001 (0.02 MB
XLS)
Table S2 Haptoglobin deletion assay-PCR conditions and
primer sequences-method adapted from Koda et al. 2000
Found at: doi:10.1371/journal.pone.0000362.s002 (0.02 MB
XLS)
Table S3 First Round and Extension Primers for G6PD, HbS,
A-61C and C-101G
Found at: doi:10.1371/journal.pone.0000362.s003 (0.02 MB
XLS)
Figure S1 Bpm1 restriction digest of plasmid colonies
Found at: doi:10.1371/journal.pone.0000362.s004 (0.22 MB TIF)
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